BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Azarbarzin S, Hosseinpour-Feizi MA, Banan Khojasteh SM, Baradaran B, Safaralizadeh R. MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1. Life Sci 2021;267:118939. [PMID: 33359245 DOI: 10.1016/j.lfs.2020.118939] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Ismail A, El-mahdy HA, Abulsoud AI, Sallam AM, Eldeib MG, Elsakka EG, Zaki MB, Doghish AS. Beneficial and detrimental aspects of miRNAs as chief players in breast cancer: A comprehensive review. International Journal of Biological Macromolecules 2022. [DOI: 10.1016/j.ijbiomac.2022.10.241] [Reference Citation Analysis]
2 Rajabi N, Mohammadnejad F, Doustvandi MA, Shadbad MA, Amini M, Tajalli H, Mokhtarzadeh A, Baghbani E, Silvestris N, Baradaran B. Photodynamic therapy with zinc phthalocyanine enhances the anti-cancer effect of tamoxifen in breast cancer cell line: Promising combination treatment against triple-negative breast cancer? Photodiagnosis and Photodynamic Therapy 2022. [DOI: 10.1016/j.pdpdt.2022.103212] [Reference Citation Analysis]
3 Jafarzadeh A, Noori M, Sarrafzadeh S, Tamehri Zadeh SS, Nemati M, Chatrabnous N, Jafarzadeh S, Hamblin MR, Jafari Najaf Abadi MH, Mirzaei H. MicroRNA-383: A tumor suppressor miRNA in human cancer. Front Cell Dev Biol 2022;10:955486. [DOI: 10.3389/fcell.2022.955486] [Reference Citation Analysis]
4 Alghazali MW, Al-Hetty HRAK, Ali ZMM, Saleh MM, Suleiman AA, Jalil AT. Non-coding RNAs, another side of immune regulation during triple-negative breast cancer. Pathol Res Pract 2022;239:154132. [PMID: 36183439 DOI: 10.1016/j.prp.2022.154132] [Reference Citation Analysis]
5 Noorolyai S, Baghbani E, Rahmani S, Shadbad MA, Montazami N, Jigari- Asl F, Vazirabad AF, Baradaran B. hsa-miR-34a-5p potentiates cytarabine-mediated cell cycle arrest in MDA-MB-231 cells: a novel combination therapy. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.154004] [Reference Citation Analysis]
6 Sun Z, Zhang S, Zhang N, Wang J, Wang J, Liu J. Circ_0005231 promotes the progression of esophageal squamous cell carcinoma via sponging miR-383-5p and regulating KIAA0101. Thorac Cancer 2022. [PMID: 35524161 DOI: 10.1111/1759-7714.14450] [Reference Citation Analysis]
7 Qiao X, Zhao F. Long non-coding RNA Opa interacting protein 5-antisense RNA 1 binds to micorRNA-34a to upregulate oncogenic PD-L1 in non-small cell lung cancer. Bioengineered 2022;13:9264-73. [PMID: 35411833 DOI: 10.1080/21655979.2022.2036904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Sun Z, Xue C, Li J, Zhao H, Du Y, Du N. LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1. Bioengineered 2022;13:7635-47. [PMID: 35266439 DOI: 10.1080/21655979.2022.2050073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Liu J, Peng X, Yang S, Li X, Huang M, Wei S, Zhang S, He G, Zheng H, Fan Q, Yang L, Li H. Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies. Cell Commun Signal 2022;20. [DOI: 10.1186/s12964-021-00816-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
10 Zhang Z, Lin J, Hu J, Liu L. Liquiritigenin Blocks Breast Cancer Progression by Inhibiting Connective Tissue Growth Factor Expression via Up-Regulating miR-383-5p. Int J Toxicol 2022;41:5-15. [DOI: 10.1177/10915818211059470] [Reference Citation Analysis]
11 Yi Q, Xie W, Sun W, Sun W, Liao Y. A Concise Review of MicroRNA-383: Exploring the Insights of Its Function in Tumorigenesis. J Cancer 2022;13:313-24. [PMID: 34976192 DOI: 10.7150/jca.64846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Patel A, Shah S. Noninvasive Biomarkers: Emerging Trends in Early Detection of Breast Cancer. Breast Cancer: From Bench to Personalized Medicine 2022. [DOI: 10.1007/978-981-19-0197-3_7] [Reference Citation Analysis]
13 Shadbad MA, Safaei S, Brunetti O, Derakhshani A, Lotfinejad P, Mokhtarzadeh A, Hemmat N, Racanelli V, Solimando AG, Argentiero A, Silvestris N, Baradaran B. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery. Genes (Basel) 2021;12:1206. [PMID: 34440380 DOI: 10.3390/genes12081206] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
14 Ashrafizadeh M, Mirzaei S, Hushmandi K, Rahmanian V, Zabolian A, Raei M, Farahani MV, Goharrizi MASB, Khan H, Zarrabi A, Samarghandian S. Therapeutic potential of AMPK signaling targeting in lung cancer: Advances, challenges and future prospects. Life Sci 2021;278:119649. [PMID: 34043989 DOI: 10.1016/j.lfs.2021.119649] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
15 Yu D, Xu Z, Cheng X, Qin J. The role of miRNAs in MDMX-p53 interplay. J Evid Based Med 2021;14:152-60. [PMID: 33988919 DOI: 10.1111/jebm.12428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Grimaldi AM, Salvatore M, Incoronato M. miRNA-Based Therapeutics in Breast Cancer: A Systematic Review. Front Oncol 2021;11:668464. [PMID: 34026646 DOI: 10.3389/fonc.2021.668464] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
17 Ashrafizadeh M, Zarrabi A, Orouei S, Zabolian A, Saleki H, Azami N, Bejandi AK, Mirzaei S, Janaghard MN, Hushmandi K, Nabavi N, Baradaran B, Kumar AP, Makvandi P, Samarghandian S, Khan H, Hamblin MR. Interplay between SOX9 transcription factor and microRNAs in cancer. Int J Biol Macromol 2021;183:681-94. [PMID: 33957202 DOI: 10.1016/j.ijbiomac.2021.04.185] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 26.0] [Reference Citation Analysis]
18 Mirzaei S, Zarrabi A, Hashemi F, Zabolian A, Saleki H, Azami N, Hamzehlou S, Farahani MV, Hushmandi K, Ashrafizadeh M, Khan H, Kumar AP. Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery. Antioxidants (Basel) 2021;10:349. [PMID: 33652780 DOI: 10.3390/antiox10030349] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 29.0] [Reference Citation Analysis]